Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - plasma homocysteine lowering intervention - all type of patients


Related trials

CSPPT, 2015 - folic acid vs placebo

VITATOPS, 2010 - folic acid, vit B12 and vit B6 vs placebo

WAFACS, 2008 - folic acid, vit B12 and vit B6 vs placebo

WENBIT (vit B6), 2008 - vit B6 vs placebo

WENBIT (folic ac,B12), 2008 - folic acid, B12 vs placebo

SEARCH, 2007 - folic acid, B12 vs placebo

NORVIT (folic acid + B12) (Bonaa), 2006 - folic acid, B12 vs control

NORVIT (folic acid, B12 and vit B6) (Bonaa), 2006 - folic acid, vit B12 and vit B6 vs control

NORVIT (vit B6) (Bonaa), 2006 - vit B6 vs control

HOPE-2 (Lonn), 2006 - folic acid, vit B12 and vit B6 vs placebo

FOLARDA (Liem), 2004 - folic acid vs control

VISP (Toole), 2004 - high dose - folic acid, vit B12 and vit B6 vs low dose - folic acid, vit B12 and vit B6

GOES (Liem), 2003 - folic acid vs control

CHAOS-2, 2002 - folic acid vs placebo

SU.FOL.OM3, - folic acid, vit B12 and vit B6 vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of plasma homocysteine lowering intervention
  • All clinical trials of folic acid
  •  
     CHAOS-2 study, 2002 TRC9988 
    download pdf: folic acid | plasma homocysteine lowering intervention for cardiovascular prevention

    Treatments

    Studied treatment folic acid 5 mg per day (for 2 years)
    Control treatment placebo

    Patients

    Patients patient with CHD
    Inclusion criteria patients with with myocardial infarction or unstable angina or with Positive coronary angiogram

    Method and design

    Randomized effectives 942 / 940 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 1.7 y
    Number of centre multicenter
    Primary endpoint CV death, MI, revascularization


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Non fatal MI

    23 / 942
    12 / 940
    classic 1,91 [0,96;3,82]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Non fatal MI 23 / 942 (2,4%) 12 / 940 (1,3%) 1,91 [0,96;3,82]   11305
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11305: Martí-Carvajal AJ, Solà I, Lathyris D, Salanti GHomocysteine lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev 2009 Oct 7;:CD006612
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of 1.7 y)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Non fatal MI 2,44% 1,28% 1,2%

    Meta-analysis of all similar trials:

    plasma homocysteine lowering intervention in cardiovascular prevention for all type of patients



    Reference(s)

    TrialResults-center ID TRC9988
    Trials register # NA
    • Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M, et al.. Baker F, Picton D, Blackwood S, Hunt J, Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial [abstract]. Circulation 2002;106(Suppl II):741.
      Pubmed | Hubmed | Fulltext

    (c) 2004-2015 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels